Get the Stockscreener App
0.8098
3.67%
0.0287
After Hours:
.81
0.0002
+0.02%
Equillium Inc stock is traded at $0.8098, with a volume of 36,276.
It is up +3.67% in the last 24 hours and down -10.01% over the past month.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
See More
Previous Close:
$0.7811
Open:
$0.8
24h Volume:
36,276
Relative Volume:
0.05
Market Cap:
$28.69M
Revenue:
$45.91M
Net Income/Loss:
$-4.62M
P/E Ratio:
-5.776
EPS:
-0.1402
Net Cash Flow:
$-21.51M
1W Performance:
+7.97%
1M Performance:
-10.01%
6M Performance:
-6.92%
1Y Performance:
-69.90%
1-Day Range:
$0.784
$0.839
1-Week Range:
$0.7252
$0.839
52-Week Range:
$0.493
$2.985
Equillium Inc Stock (EQ) Company Profile
Name
Equillium Inc
Sector
Industry
Phone
(858) 412-5302
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA, CA
Compare EQ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EQ
Equillium Inc
|
0.8098 | 28.69M | 45.91M | -4.62M | -21.51M | -0.1402 |
|
VRTX
Vertex Pharmaceuticals Inc
|
512.52 | 131.61B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.36 | 73.51B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
619.97 | 37.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.44 | 32.81B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
266.26 | 28.62B | 3.81B | -644.79M | -669.77M | -6.24 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-29-21 | Resumed | Stifel | Buy |
| Sep-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-14-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-10-20 | Resumed | Stifel | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
Equillium Inc Stock (EQ) Latest News
Equillium (EQ) to Release Quarterly Earnings on Monday - Defense World
Equillium Stock Price, Quotes and Forecasts - Benzinga
SHAREHOLDER ALERT: Weiss Law Reminds EQ, IMGO, MTCR, and OPNT Shareholders About Its Ongoing Investigations - Marketscreener.com
Equillium stock rallies 26% on itolizumab study data - MSN
Here's Why Equillium (EQ) Is a Great 'Buy the Bottom' Stock Now - Zacks Investment Research
Equillium, Inc.'s (NASDAQ:EQ) Price Is Right But Growth Is Lacking After Shares Rocket 27% - Simply Wall St
Leerink Partnrs Forecasts Stronger Earnings for Equillium - Defense World
Equillium (EQ) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Equillium (EQ) Shows Fast-paced Momentum But Is Still a Bargain Stock - Nasdaq
Healthy Upside Potential: Equillium Inc (EQ) - SETE News
Equillium Inc (EQ) Stock: Uncovering 52-Week Market Trends - The InvestChronicle
Equillium reports positive Phase 2 ulcerative colitis study data - MSN
why Borr Drilling Ltd [BORR] is a Good Choice for Investors After New Price Target of $5.23 - The DBT News
Callan JMB Inc [CJMB] gain 54.15% so far this year. What now? - The DBT News
Wall Street Analyst Resumed Equillium Inc [EQ]. What else is Wall St. saying - The DBT News
Equillium Inc [EQ] Shares Rise 33.03 % on Thursday - Knox Daily
What to expect from Equillium Inc’s (EQ) current quarter earnings? - US Post News
Insider Selling: Nachiappan Venkatachalam, Arhaus Inc [ARHS] Chief Information Officer divested 6,460 shares - Knox Daily
10% Owner HGC Next Inv LLC acquire 11,690,909 shares of NextDecade Corporation [NEXT] - Knox Daily
CuriosityStream And 2 Other Promising Penny Stocks On US Exchange - Simply Wall St
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis - StreetInsider.com
Equillium and Biocon announce positive data from Phase 2 study evaluating Itolizumab for ulcerative colitis - Indian Pharma Post
UDR Inc (UDR) Q4 2024 Earnings Call Highlights: Strong Occupancy and Strategic Growth Plans ... - Yahoo Finance UK
Biocon, Equillium announce positive data from Phase 2 Study evaluating Itolizumab for Ulcerative Colitis - Medical Dialogues
Stocks to Watch, Feb 7: Biocon, SBI, LIC, M&M, Bharti Airtel, Ola Electric - Business Standard
Equillium Reports Positive Phase 2 Results for Itolizumab in Ulcerative Colitis, Shares Surge - Yahoo Finance
Equillium reports positive Phase 2 ulcerative colitis study data By Investing.com - Investing.com South Africa
Equillium Announces Positive Data from Phase 2 Study Evaluating - GuruFocus.com
Equillium Announces Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis – Company AnnouncementFT.com - Financial Times
Lugman Group withdraws from purchase of “Industrial Park Fechenheim” - Yahoo Finance UK
Equillium Braces For Two Key Clinical Trial Data ReadoutsWill The Stock Get A Boost? - RTTNews
Equillium CFO Jason Keyes sells $6,500 in stock - MSN
Equillium CFO Jason Keyes sells $6,500 in stock By Investing.com - Investing.com Canada
Equillium stock touches 52-week low at $0.52 amid market challenges - MSN
Wall Street Analysts Predict a 75.79% Upside in Rigel (RIGL): Here's What You Should Know - MSN
Equillium (NASDAQ:EQ) Shares Down 0.9% – What’s Next? - Defense World
US Penny Stocks To Watch In January 2025 - Simply Wall St
Equillium (NASDAQ:EQ) Stock Price Down 1.6% – What’s Next? - Defense World
Equillium stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia
Equillium Announces Board and Audit Committee Changes - TipRanks
Contrasting CSL (OTCMKTS:CSLLY) and Equillium (NASDAQ:EQ) - Defense World
Why Investors Shouldn't Be Surprised By Equillium, Inc.'s (NASDAQ:EQ) 35% Share Price Plunge - Simply Wall St
Equillium CFO Jason Keyes sells $7,000 in stock By Investing.com - Investing.com Nigeria
Equillium Inc Stock (EQ) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):